CRA’s Intellectual Property experts were retained by a multinational developer and manufacturer of respiratory-related medical devices to determine economic damages in a patent infringement matter against a direct competitor. Our team developed lost profits and reasonable royalty damages models which accounted for a complex matrix of asserted patents and accused products. In determining lost profits, our team addressed demand for the patented features, market share and segmentation, and price elasticity of demand. Our team also addressed the heightened importance of the patent-practicing respiratory care medical devices amidst the global Covid-19 pandemic, including its impact on the supply chain and manufacturing capacity. CRA’s experts provided a detailed expert report and deposition testimony, and CRA’s client secured a favorable settlement just before trial.
CRA recognized in Chambers 2026 for litigation support and crisis & risk management
Charles River Associates has been recognized in the 2026 Chambers Litigation Support and Crisis & Risk Management Guides, including a Band 1 global ranking...